Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 128.85 INR
Change Today +4.25 / 3.41%
Volume 158.2K
VNR On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

venus remedies ltd (VNR) Snapshot

Open
127.80
Previous Close
124.60
Day High
137.65
Day Low
126.50
52 Week High
09/15/14 - 381.75
52 Week Low
03/23/15 - 95.60
Market Cap
1.5B
Average Volume 10 Days
127.9K
EPS TTM
4.51
Shares Outstanding
11.4M
EX-Date
09/23/14
P/E TM
28.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for VENUS REMEDIES LTD (VNR)

Related News

No related news articles were found.

venus remedies ltd (VNR) Related Businessweek News

No Related Businessweek News Found

venus remedies ltd (VNR) Details

Venus Remedies Limited manufactures and trades in medicines in India and internationally. Its product portfolio includes approximately 75 products in various therapeutic segments comprising anti-cancer, anti-infective, neurology, emergency care medicine, skin and wound care, and pain management. The company offers its products under the Mebatic, Calridol, Moximicin, Neurotol, Glutapep, Elores, Vancoplus, Potentox, Tobracef, Supime, Zydotum, Pirotum, Ronem, Lastinem, Fejet, Actimycin, Megaparin, Taxedol, Paclitol, Oxol, Citabol, Carplat, and other names. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Founded in 1989

venus remedies ltd (VNR) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: 6.3M
Joint Managing Director, Head of Venus Medici...
Total Annual Compensation: 5.9M
Whole Time Director, Member of Risk Managemen...
Total Annual Compensation: 3.2M
Deputy Managing Director, Executive Director ...
Total Annual Compensation: 3.6M
Compensation as of Fiscal Year 2015.

venus remedies ltd (VNR) Key Developments

Venus Remedies Ltd. to Report Q1, 2016 Results on Aug 14, 2015

Venus Remedies Ltd. announced that they will report Q1, 2016 results on Aug 14, 2015

Venus Remedies Ltd., Board Meeting, Aug 14, 2015

Venus Remedies Ltd., Board Meeting, Aug 14, 2015. Agenda: To consider and approve unaudited financial results (Provisional) for the quarter ended June 30, 2015.

Venus Remedies Ltd., Annual General Meeting, Aug 25, 2015

Venus Remedies Ltd., Annual General Meeting, Aug 25, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNR:IN 128.85 INR +4.25

VNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNR.
View Industry Companies
 

Industry Analysis

VNR

Industry Average

Valuation VNR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENUS REMEDIES LTD, please visit www.venusremedies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.